Bavarian Nordic’s Monkeypox Shot Is Making It a Hot Stock Again
- Shares are up 69% from a low in May with virus cases rising
- Danish company has only FDA-approved vaccine for monkeypox
This article is for subscribers only.
Bavarian Nordic A/S is having a bit of a meme-stock moment, with retail traders buying up shares in the monkeypox vaccine maker as cases of the virus steadily rise.
Shares in the Danish biotech, which makes the only monkeypox vaccine approved by the US Food and Drug Administration, have gained 69% since hitting a low in early May. At the same time, cases of the virus have jumped from just a handful in Europe at the start of last month to more than 1,200 cases, mostly in men, across the region, as well as in the Americas, the Middle East, and Australia by early June.